Latest News
Feature
Gleostine price hike draws fire
Critics say greater generic competition is needed to prevent these types of price jumps.
Conference Coverage
VIDEO: Practice changers out of ASH 2017
ATLANTA – Dr. Robert Brodsky shares his takeaways on the key practice changing data presented in the ASH 2017 late breakers.
Feature
CLL drug in limited supply outside U.S.
Patients outside the United States will be able to access the drug only through compassionate use programs.
From the Journals
Analysis of Twitter lung cancer content reveals opportunity for clinicians
Twitter conversations focused on treatment and end of life were significantly less likely to integrate cues for personal activity.
Conference Coverage
DEFUSE 3: Thrombectomy time window broadens
LOS ANGELES – Results made it into guidelines released in the same session.
Conference Coverage
mIDH inhibitors could fill treatment gap in AML
ATLANTA – A selective mIDH2 inhibitor shows promise as monotherapy, and in combination with azacitidine, in certain AML patients.
Feature
Alex Azar confirmed as HHS Secretary
Democrats on the Senate Finance Committee challenged Mr. Azar on drug prices and other issues.
Feature
Gene therapy moves from promise to reality
Dr. Cynthia Dunbar, of the NIH, talks about the “critical mass of successes” in hematology and what is coming in the future.
Conference Coverage
Circulating tumor cell assay shows promise for colorectal cancer screening
The CTC assay had an accuracy of 87.9% in the entire cohort of 620 colonoscopy patients, which included 327 patients with colorectal cancer of all...
News
FDA grants priority review to multiple myeloma treatment
Daratumumab plus VMP had exciting results at ASH. Now the FDA is fast tracking its application as a frontline multiple myeloma treatment.
Feature
Doctors to Congress: Keep Part B drug payments out of MIPS adjustment
Certain specialists stand to lose significant Medicare pay under the current policy.